Analyze the impact of 6 analyst ratings on Aclaris Therapeutics ACRS within the last quarter:

Within the last quarter, 6 analysts provided 12-month price targets for Aclaris Therapeutics. The average target is $19.17, with a high estimate of $43.00 and a low estimate of $1.00.

Learn about 6 analysts' views on Aclaris Therapeutics over the past 3 months. Increased bullish ratings reflect positive sentiment, while increased bearish ratings suggest a negative outlook.

A decline of 11.54% from the prior average price target is evident in the current average.

Interpreting Analyst Ratings: A Closer Look

Embark on a journey into the analyses of financial experts and analysts, featuring a detailed breakdown of their recent assessments for Aclaris Therapeutics. Our Ratings Table below provides a comprehensive overview of the moves made by key analysts, their present ratings, and price targets. Understanding the perceptions of these experts towards the company can unveil valuable insights into possible market trends and investor sentiment.

Key Insights:

• Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Aclaris Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Aclaris Therapeutics compared to the broader market.
• Price Targets: Delving into movements, analysts provide estimates for the future value of Aclaris Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Aclaris Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Aclaris Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

About Aclaris Therapeutics

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics: Delving into Financials

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Decline in Revenue: Over the 3 months period, Aclaris Therapeutics faced challenges, resulting in a decline of approximately -51.19% in revenue growth as of 30 September, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Aclaris Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -315.24%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Aclaris Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -17.41% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Aclaris Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -12.89% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: With a below-average debt-to-equity ratio of 0.0, Aclaris Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.

Analyst Ratings: What Are They?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.